Current status and future perspective of the chemotherapy for colorectal cancer.
In the last decade unprecedented advances have been seen in the treatment of metastatic colorectal cancer(mCRC). Clinical developments of many active agents have contributed to this great progress in the prognosis of mCRC. Recently, new active agents and combination chemotherapies have been developed and reported promising results for HER2 positive, BRAF mutant, and MSI-High mCRC patients. On the other hand, IDEA project is on-going for patients with stage II colon cancer, to answer whether a three-month course of oxaliplatin. -based adjuvant therapy (FOLFOX4/modified FOLFOX6 or XELOX) is non-inferior to the current standard six-month treatment. This chapter focuses on the current status and the future Dersoective of chemotherapy for colorectal cancer.